- •We studied EAAT2 genetic variations in patients presenting with Devic's disease.
- •Whole coding region and consensus sequences flanking each exon were sequenced.
- •No novel mutations or polymorphisms were found in EAAT2 gene.
- •No association was found between EAAT2 gene and Devic's disease.
Devic's neuromyelitis optica (NMO) is a severe inflammatory and autoimmune disease producing demyelinating lesions. Recent data suggest that a complex genetic component could be involved. While impairment of glutamate homeostasis has emerged as a contributing etiological factor in NMO, a genetic alteration of Excitatory Amino Acid Transporter 2 (EAAT2/SLC1A2), the major glutamate transporter in the Central Nervous System (CNS), could contribute to glutamate excitotoxicity and then must be considered.
We evaluated whether mutations and/or single nucleotide polymorphisms (SNPs) in EAAT2 gene, are associated with susceptibility to NMO. We studied a cohort of NMO sporadic cases including afro-caribbean patients (n=81; French cohort of Devic's neuromyelitis optica—NOMADMUS cohort) and compared to control subjects (n=56). We sequenced the whole coding region of EAAT2 gene and splicing consensus sequences flanking each exon. The results obtained from all NMO samples did not show any novel mutations and/or SNPs both in the coding region and splicing sites of EAAT2 gene compared to controls subjects. We reported three synonymous SNPs (rs752949, rs1042113 and rs7102949) but only rs7102949 was found in afro-caribbean. Genotype frequencies did not differ between patients and controls for the three SNPs in caucasians and afro-caribbeans (rs752949: p=0.71 and p=0.37, respectively; rs1042113: p=0.73 and p=0.35, respectively; rs7102949: p=0.08 in afro-caribbeans). Our data showed no evidence for a genetic association between EAAT2 gene and Devic's neuromyelitis optica.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population.Multiple Sclerosis. 2010; 17: 24-31
- Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.Journal of Experimental Medicine. 2008; 205: 2473-2481
- Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica.Neurobiology of Disease. 2009; 37: 349-355
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.Lancet. 2004; 364: 2106-2112
- Familial neuromyelitis optica.Neurology. 2010; 75: 310-315
- Genetic analysis of aquaporin-4 in neuromyelitis optica.Neurology. 2011; 77: 1149-1155
- Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.Brain. 2010; 133: 2578-2591
- Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis.Journal of Neuroimmunology. 2008; 195: 194-198
- Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica.Journal of Biological Chemistry. 2011; 286: 45156-45164
- A response to “association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis”.Journal of Neuroimmunology. 2008; 203: 116-117
- Revised diagnostic criteria for neuromyelitis optica.Neurology. 2006; 66: 1485-1489
- The spectrum of neuromyelitis optica.Lancet Neurology. 2007; 6: 805-815
Published online: July 22, 2013
Accepted: June 21, 2013
Received in revised form: May 20, 2013
Received: November 6, 2012
© 2013 Elsevier B.V. Published by Elsevier Inc. All rights reserved.